Pfizer: Potential Double-Digit Upside Combined With High Dividend Yield


  • Pfizer’s stock has struggled to recover since the pandemic, but its high dividend yield of 5.9% makes it an attractive option for income investors.
  • The company faces risks from upcoming patent expiries and the impact of rising interest rates on its debt and ability to invest in research and development.
  • Despite these challenges, Pfizer’s valuation metrics suggest it is attractively priced, and a dividend discount model estimates a potential upside of over 30% from the current price level.

Pfizer world headquarters in New York City, USA.



Pfizer (NYSE:PFE) (NEOE:PFE:CA) has struggled to gain any sort of recovery momentum since it suffered losses in revenue coming off the tail end of the pandemic. In addition, the upcoming patent expiries seem to be a

Product US Expiration Year Europe Expiration Year Japan Expiration Year
Inlyta 2025 2025 2025
Xeljanz 2025 2028 2025
Prevnar 13 2026 2029
Eliquis 2026 2026 2026

Analyst’s Disclosure: I/we have a beneficial long position in the shares of PFE either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Leave a Reply

Your email address will not be published. Required fields are marked *